These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1342 related articles for article (PubMed ID: 18313315)

  • 1. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
    Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
    Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
    Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
    Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
    Park SS; Lee D
    Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R; Mohapel P; Brundin P; Paul G
    Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
    Steiner B; Winter C; Hosman K; Siebert E; Kempermann G; Petrus DS; Kupsch A
    Exp Neurol; 2006 Jun; 199(2):291-300. PubMed ID: 16360152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
    Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
    Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
    Locke CJ; Fox SA; Caldwell GA; Caldwell KA
    Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
    Liu CQ; Chen Z; Liu FX; Hu DN; Luo JH
    Neuropharmacology; 2007 Dec; 53(7):832-41. PubMed ID: 17919665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
    Park SS; Schulz EM; Lee D
    Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.